Israeli research: ‘Natural compounds’ could kill COVID-19 spike protein

The news comes against the backdrop of both skyrocketing infection in Israel and a mass vaccination campaign.

The IP Challenge in Patents For Repurposed Drugs and DRPx products

By: Dr. Hadassa Waterman, Head of the Biotech Department, Ehrlich & Fenster of Ehrlich Group Drug repurposing has been around for centuries. However, a recent report shows that in the...

Israeli entrepreneurs race to protect potential Coronavirus solutions

The Ehrlich Group has filed approximately 30 patent applications for coronavirus-related technologies, on behalf of dozens of Israeli entrepreneurs.